Código QR (código de barras bidimensional)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Abstract Introduction Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared the long-term efficacy of deucravacitinib and adalimumab using results from long-term extension (LTE...

תיאור מלא

שמור ב:
Principais autores: April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov
פורמט: Artigo
שפה:Inglês
יצא לאור: Adis, Springer Healthcare 2023-07-01
סדרה:Dermatology and Therapy
נושאים:
Adalimumab
Deucravacitinib
Indirect comparison
MAIC
Plaque psoriasis
גישה מקוונת:https://doi.org/10.1007/s13555-023-00977-1
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים